Vivici, a company specializing in animal-free dairy alternatives, has received a “no questions” letter from the US Food and Drug Administration (FDA) for its cow-free whey product. This milestone comes amidst the FDA’s overhaul of its Generally Recognized as Safe (GRAS) notification process. A “no questions” letter is a favorable designation from the FDA, indicating that the agency has reviewed Vivici’s submission and has no further questions or concerns regarding the safety of their product.
The FDA’s GRAS reform aims to modernize the notification process, making it more efficient and transparent. Vivici’s success in securing a “no questions” letter demonstrates the company’s compliance with the FDA’s rigorous guidelines. The achievement enables Vivici to market its animal-free whey product in the US, offering a sustainable and dairy-free alternative for the food industry. This development has significant implications for the dairy-free and plant-based food sector, as well as for consumers seeking to reduce their environmental impact and adapt to changing consumer preferences.